Diabetes News October 2nd 2009

Clinical Practice Consensus Guidelines 2009
18 chapters for download (International Society for Pediatric and Adolescent Diabetes)

Prescribing for Diabetes in England – An Update: 2002-2008
An analysis of volume, expenditure and trends June 2009 (Yorkshire and Humber Public Health Observatory, UK)

The Scottish Health Survey 2008
Including diabetes (Scottish Government, UK)

£19 million to the MRC/CSO Social & Public Health Sciences Unit
The SPHSU is based at the University of Glasgow – Current research projects at the Unit focus on major health problems that exist in developed (and also developing) countries, including cancer, heart disease and stroke, obesity and diabetes, sexual health and mental illness (MRC)

Welsh Health Survey 2008
Including statistics for diabetes (Welsh Assembly Government)

Diabetes and obesity rates soar
The number of people diagnosed with diabetes in the UK has increased by more than 145,000 in the last year (Daibetes UK)

Early responses of insulin sensitivity to high-carbohydrate and high-fat overfeeding
We conclude that acute bouts of overnutrition lead to changes at the cellular level before whole-body insulin sensitivity is altered (Nutrition and Metabolism)

Updated prescribing information regarding acute pancreatitis and sitagliptin
The FDA is revising the prescribing information for Januvia (sitagliptin) and Janumet (sitagliptin/metformin) to include information on reported cases of acute pancreatitis in patients using these products (American Diabetes Association)

Rosiglitazone and pioglitazone
Beware macular oedema (Letter, BMJ, UK)

Boehringer Ingelheim’s diabetes pipeline continues to advance
Following the release of linagliptin phase II data earlier this year, Boehringer Ingelheim has now announced the conclusion of the linagliptin pivotal phase III clinical trials (Pharmacy Europe)

Changing Lives: Diabetes Pill
Oramed’s insulin capsule seeks to revolutionize treatment (Video – CEO Insights, Forbes, USA)

Efficacy and Safety of AIR Inhaled Insulin Compared to Insulin Lispro in Patients with Type 1 Diabetes Mellitus
Insulin lispro provided lower A1C than AIR insulin, but the difference may not be clinically relevant (Diabetes Technology & Therapeutics)

The Diabetes Mellitus Medication Choice Decision Aid
An innovative decision aid effectively involved patients with type 2 diabetes mellitus in decisions about their medications but did not improve adherence or HbA1c levels (Archives of Internal Medicine)

Cardiovascular Manifestations of Insulin Resistance
Studies such as the Nurses’ Health Study show that even slight glucose abnormalities, namely insulin resistance, increase the risk of myocardial infarctions, strokes, other cardiovascular disease, and mortality (American Journal of Therapeutics)

Sanofi-aventis launches major insulin research program in partnership with the international scientific community
Sanofi-aventis announced that the company’s action plan to provide methodologically robust research that will contribute to the scientific resolution of the debate over insulin safety, including insulin analogs and Lantus® (insulin glargine) (PharmaLive)

Influence of insulin on cancer risk
Possible protection from cancer with metformin examined (Endocrine Today)

Diamyd makes investment in time-to-market
Diamyd Medical announces today that the company has signed an agreement with Inclinix Inc., North Carolina, for accelerated recruitment of children and adolescents recently diagnosed with type 1 diabetes in the US Phase III study of the diabetes vaccine (Diamyd)